Stephen Barat, PhD

Dr. Barat has served as HTG's SVP of Therapeutics since October 2021. Prior to HTG, Dr. Barat was the U.S. Head, Non-clinical Safety Leaders at Janssen, where he led a large team that supported programs in all phases of discovery and development, from target assessment through candidate selection, early/late-stage development and registration. Before Janssen, he served as VP Preclinical Research and Early Development at Scynexis and held additional senior roles at Allergan (Actavis/Forest Laboratories) and Schering-Plough/Merck. During his career, Dr. Barat has contributed to the development and registration of 15 new drug products and has been an active member of industry working groups with USP and PQRI. A graduate of Rutgers University, Dr. Barat earned his Ph.D. in pharmacology and toxicology from the University of Medicine and Dentistry - New Jersey Medical School.